Explanipedia

MON-567 Diabetes After Heart Transplantation Is an Increasingly Common Issue Open

Lisa M. Raven, Andrew Jabbour, Peter S. Macdonald, Christopher A. Muir, Jerry R. Greenfield · 2025

Disclosure: L.M. Raven: None. A. Jabbour: None. P.S. Macdonald: None. C.A. Muir: None. J.R. Greenfield: None. Background: Heart transplantation (HTx) survival rates have improved over the last 20 years with advances in immunosuppression an…

Diabetes is an Increasingly Common Issue After Heart Transplantation: A Case for Integrated Diabetes Care Open

Lisa M. Raven, Andrew Jabbour, Peter S. Macdonald, Jerry R. Greenfield, Christopher A. Muir · 2025

Sodium glucose cotransporter 2 inhibitor use after heart transplant: Current knowledge and potential applications Open

Lisa M. Raven, Lina Brinker, Konstantinos Sideris, Christopher A. Muir, Spencer Carter , et al. · 2025

Heart transplant (HTx) markedly improves survival and quality of life in patients with stage D heart failure. However, long-term survival post-HTx is limited by increased risk and progression of cardiovascular disease, chronic kidney disea…

Management of diabetic ketoacidosis in adult inpatients: A retrospective analysis of rates of hypoglycaemia with variable‐rate and fixed‐rate intravenous insulin infusion protocols Open

Stephanie Baddock, Lisa M. Raven, Gimhani Abeygunasekara, Michel Roche, Carolyn J. Petersons · 2025

Aims To compare variable‐rate intravenous insulin infusion (VRIII) to fixed‐rate intravenous insulin infusion (FRIII) on the incidence of hypoglycaemia during DKA management. Secondary outcomes were time to resolution of ketosis and hospit…

Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation Open

Lisa M. Raven, Jerry R. Greenfield, Andrew Jabbour, Peter S. Macdonald, Christopher A. Muir · 2025

Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both ar…

Heterogeneity in the management of diabetic ketoacidosis in Australia: a national survey Open

Lisa M. Raven, William Lever, Richard J. MacIsaac, Jerry R. Greenfield, Adam Deane , et al. · 2025

Background Diabetic ketoacidosis (DKA) is a hyperglycaemic emergency, and insulin administration is highly protocolised with either variable‐ or fixed‐rate intravenous infusions. There are limited data supporting superiority of one regimen…

Romosozumab as Treatment for Severe Osteoporosis in Heart and Lung Transplant Recipients Open

Lisa M. Raven, Jacqueline R. Center, Christopher A. Muir · 2025

Background: Osteoporosis is common in transplant recipients, and fracture risk is high. Standard treatment is with anti-resorptive medications. Despite high fracture rates, there are limited data on the use of anabolic bone therapies in tr…

Association of early post‐transplant hyperglycaemia and diabetes mellitus on outcomes following heart transplantation Open

Christopher A. Muir, William Kuang, K. Muthiah, Jerry R. Greenfield, Lisa M. Raven · 2024

Aims Early post‐transplant hyperglycaemia (EPTH) and post‐transplant diabetes mellitus (PTDM) are common following solid organ transplantation and may be associated with adverse outcomes. We studied the prevalence of EPTH and cumulative 5‐…

Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation Open

Lisa M. Raven, Christopher A. Muir, Ricardo Deveza, Cassia Kessler Iglesias, N. Bart , et al. · 2024

Teriparatide as Treatment for Severe Osteoporosis in Lung Transplant Recipients Open

Lisa M. Raven, Louise Goodall, Jacqueline R. Center, Christopher A. Muir · 2024

Osteoporosis and osteopenia are common in lung transplant (LTx) recipients, with a significantly increased incidence compared to other non-lung solid organ transplant patients. Despite high fracture rates, including in patients treated wit…

Fournier’s gangrene in recent transplant recipient on empagliflozin Open

Lisa M. Raven, Jacob Cao, Peter S. Macdonald, Andrew Jabbour, Jerry R. Greenfield · 2024

Considerations of delayed gastric emptying with peri‐operative use of glucagon‐like peptide‐1 receptor agonists Open

Lisa M. Raven, Campbell Brown, Jerry R. Greenfield · 2023

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), such as semaglutide, dulaglutide and liraglutide, augment glucose-dependent β-cell insulin release, suppress glucagon secretion, and slow gastric emptying. In Australia, they are ava…

SGLT2 Inhibitor–Induced Ketoacidosis in a Patient Without Diabetes Open

Annabelle G Hayes, Lisa M. Raven, Alexander Viardot, Eugene Kotlyar, Jerry R. Greenfield · 2023

THU441 Teriparatide As Treatment For Severe Osteoporosis In Lung Transplant Recipients Open

Christopher A. Muir, Lisa M. Raven, Louise Goodall, Jacqueline R. Center · 2023

Disclosure: C.A. Muir: None. L.M. Raven: None. L. Goodall: None. J.R. Center: None. Background: Lung transplantation (LTx) is a life-saving treatment for end-stage pulmonary disease. With improvements in immunosuppression, LTx survival con…

THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design Open

Lisa M. Raven, Christopher A. Muir, Cassia Kessler Iglesias, Eugene Kotlyar, K. Muthiah , et al. · 2023

Disclosure: L.M. Raven: None. C.A. Muir: None. C. Kessler Iglesias: None. E. Kotlyar: None. K. Muthiah: None. N.K. Bart: Advisory Board Member; Self; Bristol-Myers Squibb. Grant Recipient; Self; Pfizer, Inc. Speaker; Self; Pfizer, Inc. P.S…

Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists Open

Lisa M. Raven, Alina Stoita, Robert B Feller, Campbell Brown, Jerry R. Greenfield · 2023

Sodium glucose cotransporter 2 inhibitor‐induced ketoacidosis is unlikely in patients without diabetes Open

Lisa M. Raven, Christopher A. Muir, Jerry R. Greenfield · 2023

Sodium glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, dapagliflozin, ertugliflozin and canagliflozin, increase urinary excretion of glucose by inhibiting reabsorption from renal proximal tubules. Glycaemic, cardiovascul…

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial Open

Lisa M. Raven, Christopher A. Muir, Cassia Kessler Iglesias, N. Bart, K. Muthiah , et al. · 2023

Introduction Cardiac transplantation (CTx) is a life-saving operation that can improve the quality and length of a recipient’s life. Immunosuppression medication, required to prevent rejection, can result in adverse metabolic and renal eff…

Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors in Bridge-To-Transplant Patients Supported with Centrifugal-Flow Left Ventricular Assist Devices Open

Sanjay Chavali, Sumita Barua, Audrey Adji, D. Robson, Lisa M. Raven , et al. · 2023

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes Open

Lisa M. Raven, Jerry R. Greenfield, Christopher A. Muir · 2022

The efficacy of glucagon-like peptide-1 receptor agonists in type 2 diabetes is well established, but their role in type 1 diabetes (T1DM) is less clear. A 36-year-old woman with a 27-year history of T1DM and undetectable c-peptide present…

Female Representation: Australian Diabetes and Endocrinology Societies Open

Lisa M. Raven, Ann McCormack · 2022

Background Endocrinology has one of the highest proportions of female specialists and trainees, however females have traditionally been underrepresented in leadership positions and as speakers at scientific meetings. Hypothesis Females wou…

Letter to the Editor From Raven et al: “Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine” Open

Lisa M. Raven, Ann McCormack, Jerry R. Greenfield · 2021

Lisa M. Raven YOU? Author Swipe